5 insights from JPM 2025
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
rare disease
Enabling every cure for community matters: Our AI-powered journey
Vibe Bio is doing extraordinary work to change drug development: from funding next-generation therapies to helping others identify the highest potential cures.
Revolutionizing Drug Development for Rare Diseases Through AI | Alok Tayi
“In this episode, Alok shares his personal story of how medical conditions in his family led to the creation of Vibe Bio, and how the company aims to identify diseases with unmet needs, leveraging AI to find medicines with the highest chances of providing cures.”
Developing a Small Molecule for Duchenne Muscular Dystrophy with Frank Gleeson | VibeCast Episode 48
Frank Gleeson, Co-Founder and CEO of Satellos Bioscience, discusses groundbreaking small molecule therapies for Duchenne muscular dystrophy.
The Biotech Startups Podcast with guest Alok Tayi, Founder & CEO of Vibe Bio
Learn how Vibe Bio is tackling the problem of funding & guiding high potential drug programs.
STAT – Upending drug industry financing
This article looks at how Vibe Bio CEO, Alok Tayi, is seeking to upend drug industry financing.
Forbes – Alok Tayi’s new start-up is putting drug development into patients’ hands
This article examines how Vibe Bio’s Founder and CEO is putting drug development into patients’ hands.
Endpoint News – Parents become drug developers to save their children’s lives
Endpoint News addressed how parents of children with rare disease are challenging the status quo in drug development.
Coindesk – How Vibe Bio plans to retool biotech funding
In this article, Vibe Bio founder and CEO, Alok Tayi, explains how a decentralized science approach can retool biotech funding.
The Scoop – A conversation with Alok Tayi
“In this episode of The Scoop, Tayi shares his vision for how Vibe Bio aims to disrupt the centralized control of big pharma”